Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Core Insights - NanoViricides, Inc. has made significant advancements in its antiviral research, as highlighted by CEO Dr. Anil Diwan in a recent video interview [1] Company Progress - The company is publicly traded on NYSE American under the ticker NNVC [1] - Dr. Anil Diwan discussed the major progress in the company's antiviral research during the interview with Steve Darling from Proactive [1]